BioNTech für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2PSR2 / ISIN: US09075V1026

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Orderbuch	Analysen
Historisch

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Orderbuch
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BioNTech (ADRs)

25.05.23		Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023 (RSS)
08.05.23		BioNTech Announces First Quarter 2023 Financial Results and Corporate Update (RSS)
24.04.23		BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023 (RSS)
03.04.23		BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors (RSS)
28.03.23		BioNTech Announces New ADS Repurchase Program (RSS)
27.03.23		BioNTech-Aktie verliert: BioNTech 2022 mit Umsatz- und Gewinnrückgang (finanzen.at) Der Biotechnologikonzern BioNTech hat am Montag vor US-Börsenstart seine Bücher geöffnet.» mehr
27.03.23		BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update (RSS)
20.03.23		BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications (RSS)
14.03.23		Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
13.03.23		BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023 (RSS)
01.03.23		BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel (RSS)
01.03.23		Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
21.02.23		NASDAQ-Titel BioNTech-Aktie dreht letztlich dennoch ins Minus: BioNTech plant Behandlung von Patienten mit personalisierten mRNA-Krebsimmuntherapien (finanzen.at) Das Mainzer Biotech-Unternehmen will schon bald mit klinischen Studien zu seiner mRNA-Krebsimpfung in Großbritannien starten und zeigt sich zuversichtlich hinsichtlich der Wirksamkeit seiner neuartigen Krebstherapie.» mehr
10.02.23		Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program (RSS)
02.02.23		BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility (RSS)
23.01.23		German Chancellor Olaf Scholz to Visit BioNTech: Construction of First Proprietary Plasmid DNA Production Completed (RSS)
10.01.23		BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development (RSS)
06.01.23		BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030 (RSS)
28.12.22		BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference (RSS)
23.12.22		BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165 (RSS)
23.12.22		Montauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider Foundation (RSS)
22.12.22		BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China (RSS)
21.12.22		Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use (RSS)
16.12.22		BioNTech Announces Plans for a Clinical Trial hub in Taiwan for mRNA-based Cancer Immunotherapies as Part of Asia-Pacific Expansion (RSS)
09.12.22		Tilray Brands' Stockholders Approve Reverse Stock Split; Company Pauses Implementation as It Evaluates Timing and Stock Price (RSS)
08.12.22		Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
05.12.22		Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
30.11.22		4: Statement of changes in beneficial ownership of securities (RSS)
18.11.22		4: Statement of changes in beneficial ownership of securities (RSS)
17.11.22		Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection (RSS)
14.11.22		Tilray Brands to Present at TD Cowen’s 9th Annual Future of the Consumer Conference (RSS)
11.11.22		BioNTech and Fosun Pharma Receive Emergency Use Authorization for Omicron-BA.4/BA.5 Adapted Bivalent Vaccine in Hong Kong and Special Import Authorization for Macau (RSS)
10.11.22		Tilray Medical Brings Canada’s Iconic Cannabis Brand Good Supply to Germany (RSS)
07.11.22		BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update (RSS)
04.11.22		Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine (RSS)
03.11.22		Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19 (RSS)
24.10.22		DEF 14A: Official notification to shareholders of matters to be brought to a vote ("Proxy") (RSS)
19.10.22		Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union (RSS)
13.10.22		Terrapin Beer Co. Celebrates 23 Years of Craft Beer and Environmental Stewardship with Terraprint Initiative and Orvis Partnership (RSS)
12.10.22		Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age (RSS)
12.10.22		Hoffnungsträger gegen Corona: Die Geschichte von BioNTech (finanzen.at) Im November 2020 erreichte die Welt eine hoffnungsvolle Nachricht im Kampf gegen die Pandemie: Der Impfstoff von BioNTech war reif für das Zulassungsverfahren und wird inzwischen bereits in mehreren Ländern verabreicht. Das Unternehmen aus Mainz hat einen kometenhaften Aufstieg hinter sich - und zwar nicht erst durch die Pandemie.» mehr
07.10.22		BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility (RSS)
28.09.22		Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (RSS)
26.09.22		Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (RSS)
16.09.22		Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union (RSS)
12.09.22		Tilray Brands Reports Q3 Fiscal 2025 Financial Results (RSS)
09.09.22		Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec (RSS)
07.09.22		BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines (RSS)
01.09.22		Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union (RSS)
31.08.22		Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older (RSS)

Erste Seite Zurück | ... | 2 | 3 | 4 | 5 | Weiter

Newssuche

BioNTech Peer Group Nachrichten

17:09		BioNTech-Aktie fester: UBS belässt Einstufung für BioNTech unverändert
10:04		SMI-Wert Roche-Aktie: So viel Verlust hätte ein Investment in Roche von vor 5 Jahren eingebracht
10:04		DAX 40-Papier Bayer-Aktie: So viel Verlust hätte ein Investment in Bayer von vor 10 Jahren bedeutet
21.08.25		Bayer-Aktie fester: Fitch bestätigt Bayer-Bonität - BBB-Rating mit stabiler Prognose
20.08.25		Dow Jones 30 Industrial-Wert Johnson Johnson-Aktie: So viel Gewinn hätte ein Johnson Johnson-Investment von vor 10 Jahren abgeworfen
19.08.25		S&P 500-Titel Pfizer-Aktie: So viel Verlust wäre bei einem Investment in Pfizer von vor 5 Jahren angefallen
19.08.25		EURO STOXX 50-Wert Sanofi-Aktie: So viel Verlust hätte ein Investment in Sanofi von vor einem Jahr eingebracht
19.08.25		DAX 40-Wert Fresenius SE-Aktie: So viel Gewinn hätte eine Fresenius SE-Investition von vor 3 Jahren eingebracht

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.08.2025 18:56
Kaufwert:	EUR
	Hinzufügen Speichern

BioNTech Aktie

WKN DE: A2PSR2 / ISIN: US09075V1026

Nachrichten zu BioNTech (ADRs)

Newssuche

BioNTech Peer Group Nachrichten

Meistgelesene Nachrichten